BIOR News and Press, Biora Therapeutics Inc. From 05/07/24

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the first quarter ended March 31, 2024. The company’s ...

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data on device function of the NaviCap™ Targeted Oral Delivery Platform at Digestive Disease...

Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024 SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, ...

2024-04-09 08:30:03 ET H.C. Wainwright analyst issues BUY recommendation for BIOR on April 9, 2024 06:37AM ET. The previous analyst recommendation was Buy. BIOR was trading at $0.7257 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...

2024-04-08 16:26:54 ET More on Biora Therapeutics Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript Biora Therapeutics wins new patent covering Biojet liquid jet delivery technology Biora Therapeutics reports positive results from its clinical trial of...

2024-04-08 11:10:50 ET More on Biora Therapeutics Biora Therapeutics reports positive results from its clinical trial of BT-600 Biora Therapeutics announces $6M registered direct offering and concurrent private placement Seeking Alpha’s Quant Rating on Biora T...

SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeu...

2024-04-04 08:55:21 ET More on Biora Therapeutics Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript Biora Therapeutics announces $6M registered direct offering and concurrent private placement Biora Therapeutics announces new capital investment ...

All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no safety signals observed Multiple-ascending dose (MAD) portion of the trial ...

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously announced registered direct offering of an aggregate of 5,454,548 shares of the Company’s ...